JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266577

Human LUC7L2 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

LUC7L2 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

View Alternative Names

CGI 59, CGI 74, FLJ10657, LC7L2_HUMAN, LUC7 like 2 (S. cerevisiae), LUC7B2, Putative RNA-binding protein Luc7-like 2, hLuc7B2

1 Images
Sanger Sequencing - Human LUC7L2 knockout HEK-293T cell line (AB266577)
  • Sanger seq

Unknown

Sanger Sequencing - Human LUC7L2 knockout HEK-293T cell line (AB266577)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266577-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266577 Human LUC7L2 knockout HEK-293T cell line", "number":"AB266577-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266577-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266577 Human LUC7L2 knockout HEK-293T cell line", "number":"AB266577-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
LUC7L2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LUC7L2 also known as LUC7-like 2 is an RNA-binding protein that plays a role in RNA splicing. It has a molecular mass of approximately 27 kDa. LUC7L2 is expressed in a variety of tissues with a higher expression in the brain and reproductive tissues. It has a specific domain structure that enables it to bind to RNA molecules influencing pre-mRNA processing. The protein is also known to interact with other splicing factors contributing to its function in the cellular nucleus.
Biological function summary

LUC7L2 is an important factor in the regulation of gene expression. It is part of the spliceosome complex which is responsible for the precisely regulated removal of introns from pre-mRNA. This activity impacts the generation of mature mRNA and consequently protein synthesis. LUC7L2 interacts with other components of the spliceosome like the U1 snRNP which ensures accurate and efficient splicing. Through these interactions LUC7L2 helps maintain the fidelity of the splicing process affecting cell function and health.

Pathways

LUC7L2 participates in the mRNA splicing pathway also known as the spliceosome cycle. This protein is involved in both the recognition of splice sites and the catalytic steps of splicing. LUC7L2's activity influences alternative splicing patterns which diversifies the proteome. It interacts with other proteins like the SR proteins which modulate splicing decisions. Its role in the spliceosome cycle highlights its contribution to gene expression regulation.

LUC7L2 has been implicated in neurological disorders and certain cancers. Alterations in LUC7L2 expression or function can lead to aberrant splicing events that disrupt normal cellular activity. In some cancers LUC7L2's interaction with proteins like SF3B1 another spliceosomal component becomes dysregulated contributing to tumorigenesis. Understanding LUC7L2's function and interactions may help develop therapeutic strategies for conditions linked to splicing dysregulation.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com